Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013791967> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3013791967 abstract "Background Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Surprisingly, the overall survival (OS) advantage of ribociclib was reported in the MONALEESE-7 trial. This study was conducted to further evaluate the efficacy and safety of CDK4/6 inhibitors for HR+/HER2- ABC. MethodWe searched PUBMUD, MEDLINE, EMBASE et al to identify relevant randomized controlled trials that compared CDK4/6 inhibitors plus ET to ET alone in HR+/HER2- ABC. We extracted the hazard ratios (HRs) for progression-free survival (PFS) and OS, and risk ratios (RRs) for objective response rate (ORR), clinical benefit rate (CBR), adverse events (AEs). Statistical analysis was performed with random-effects model. Heterogeneity was assessed by I2 statistic. Result Eight trials and 4,580 patients were included in this meta-analysis. Both PFS (HR=0.54, 95% confidence interval [CI]: 0.50-0.59, p Citation Format: Li Jing, Fu Fangmeng, Yu Liuwen, Huang Meng, Lin Yuxiang, Mei Qian, Lv Jinxing, Wang Chuan. The efficacy and safety of selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC): A systematic review and meta-analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-11-16." @default.
- W3013791967 created "2020-04-03" @default.
- W3013791967 creator A5004467304 @default.
- W3013791967 creator A5009807782 @default.
- W3013791967 creator A5016096304 @default.
- W3013791967 creator A5018898877 @default.
- W3013791967 creator A5030656766 @default.
- W3013791967 creator A5034283242 @default.
- W3013791967 creator A5048223283 @default.
- W3013791967 creator A5080485014 @default.
- W3013791967 date "2020-02-14" @default.
- W3013791967 modified "2023-09-27" @default.
- W3013791967 title "Abstract P5-11-16: The efficacy and safety of selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC): A systematic review and meta-analysis" @default.
- W3013791967 doi "https://doi.org/10.1158/1538-7445.sabcs19-p5-11-16" @default.
- W3013791967 hasPublicationYear "2020" @default.
- W3013791967 type Work @default.
- W3013791967 sameAs 3013791967 @default.
- W3013791967 citedByCount "0" @default.
- W3013791967 crossrefType "proceedings-article" @default.
- W3013791967 hasAuthorship W3013791967A5004467304 @default.
- W3013791967 hasAuthorship W3013791967A5009807782 @default.
- W3013791967 hasAuthorship W3013791967A5016096304 @default.
- W3013791967 hasAuthorship W3013791967A5018898877 @default.
- W3013791967 hasAuthorship W3013791967A5030656766 @default.
- W3013791967 hasAuthorship W3013791967A5034283242 @default.
- W3013791967 hasAuthorship W3013791967A5048223283 @default.
- W3013791967 hasAuthorship W3013791967A5080485014 @default.
- W3013791967 hasConcept C121608353 @default.
- W3013791967 hasConcept C126322002 @default.
- W3013791967 hasConcept C143998085 @default.
- W3013791967 hasConcept C197934379 @default.
- W3013791967 hasConcept C207103383 @default.
- W3013791967 hasConcept C23589133 @default.
- W3013791967 hasConcept C2775930923 @default.
- W3013791967 hasConcept C2776694085 @default.
- W3013791967 hasConcept C2779744173 @default.
- W3013791967 hasConcept C2780739268 @default.
- W3013791967 hasConcept C44249647 @default.
- W3013791967 hasConcept C530470458 @default.
- W3013791967 hasConcept C71924100 @default.
- W3013791967 hasConceptScore W3013791967C121608353 @default.
- W3013791967 hasConceptScore W3013791967C126322002 @default.
- W3013791967 hasConceptScore W3013791967C143998085 @default.
- W3013791967 hasConceptScore W3013791967C197934379 @default.
- W3013791967 hasConceptScore W3013791967C207103383 @default.
- W3013791967 hasConceptScore W3013791967C23589133 @default.
- W3013791967 hasConceptScore W3013791967C2775930923 @default.
- W3013791967 hasConceptScore W3013791967C2776694085 @default.
- W3013791967 hasConceptScore W3013791967C2779744173 @default.
- W3013791967 hasConceptScore W3013791967C2780739268 @default.
- W3013791967 hasConceptScore W3013791967C44249647 @default.
- W3013791967 hasConceptScore W3013791967C530470458 @default.
- W3013791967 hasConceptScore W3013791967C71924100 @default.
- W3013791967 hasLocation W30137919671 @default.
- W3013791967 hasOpenAccess W3013791967 @default.
- W3013791967 hasPrimaryLocation W30137919671 @default.
- W3013791967 hasRelatedWork W10148955 @default.
- W3013791967 hasRelatedWork W11917847 @default.
- W3013791967 hasRelatedWork W13534514 @default.
- W3013791967 hasRelatedWork W14023476 @default.
- W3013791967 hasRelatedWork W14057612 @default.
- W3013791967 hasRelatedWork W14649502 @default.
- W3013791967 hasRelatedWork W16270628 @default.
- W3013791967 hasRelatedWork W2083469 @default.
- W3013791967 hasRelatedWork W2337926 @default.
- W3013791967 hasRelatedWork W7729919 @default.
- W3013791967 isParatext "false" @default.
- W3013791967 isRetracted "false" @default.
- W3013791967 magId "3013791967" @default.
- W3013791967 workType "article" @default.